Bardzo tanie apteki z dostawą w całej Polsce **kupic levitra** i ogromny wybór pigułek.

## Microsoft word - assignments_2013.docx

**ASSIGNMENT 2 for **Marianna Marra

The dataset ear.dat is based on 214 children with acute otitis media (OME) who
participated in a randomized clinical trial (Mandel et.al., 1982,Pedriatic Infectious Diseases, 1,
310-316). Each child had OME at the beginning of the study in either one (unilateral cases) or
both (bilateral cases) ears. Each child was randomly assigned to receive a 14-days course of one
of antibiotic, either cefaclor (CEF) or amoxicillin (AMO). The focus here is on the 203 children
whose middle ear status was determined at a 14-day follow up visit. The data have the following
Column Variable Format or Code ------------------------------------------------------------------------- 1-3 ID 5 Clearance by 14 days 1=yes/0=no 7 Antibiotic 1=CEF/2=AMO 9 Age 1=<2 yrs/2=2-5 yrs/3=6+ yrs 11 Ear 1=1st ear/2=2nd ear ------------------------------------------------------------------------
1. Construct a model in WinBUGS to estimate the efficiency of the drug treatment
considering also other possible risk factors. Assume two models: one with no correlation between the two ears and one by introducing correlation via random effects. What are the differences between the two models? Are random effects necessary here?
2. Perform Bayesian variable selection to estimate the covariates. Specify carefully your
prior and also perform sensitivity analysis on different values of the prior variance. What is your final conclusion?
3. Interpret the results of the median probability model, maximum-a-posteriori model and

**ASSIGNMENT 2 for **Flavia Fornaciari

Implement the Bayesian variable selection methods to estimate which model and which variables should be included in the model. Be careful with the prior selection and also conduct a sensitivity analysis.
Interpret the posterior results for the Median probability and the Maximum a-posteriori models (if different).
Repeat the same analysis for the same for the model averaged coefficients.
Compare the results with the true expression used to generate the data:

**ASSIGNMENT 2 for **Ilaria Masiami

athens.aueb.gr/~jbn/winbugs_book/home.html). The data were compiled from a customer
satisfaction survey contacted in Chios, Greece (Sarantinidis, 2003). The given dataset is only
part of the original dataset. Explanation of the variables is provided in file

**mshop1.txt**.

• Build an ANCOVA model and identify which variables influence the total money spent
using Bayesian variable selection methods. Be careful with the prior specification.
Conduct also sensitivity analysis on the results.
• Interpret the posterior results for the Median probability and the Maximum a-posteriori
• Repeat the same analysis for the same for the model averaged coefficients.

**ASSIGNMENT 2 for **Riccardo

Implement the Bayesian variable selection methods to estimate which model and which variables should be included in the model. Be careful with the prior selection and also conduct a sensitivity analysis.
Interpret the posterior results for the Median probability and the Maximum a-posteriori models (if different).
Repeat the same analysis for the same for the model averaged coefficients.
Compare the results with the true expression used to generate the data:

Source: http://elearning.sta.uniroma1.it/moodle2/pluginfile.php/5903/mod_folder/content/3/Assignment2_2013.pdf?forcedownload=1

Protocol Version 1.1 Synopsis Plasma exchange and glucocorticoid dosing in the treatment of ANCA-associated vasculitis: a multicentre randomised controlled trial - PEXIVAS Multi-centre, international, phase III, open label, 2x2 factorial, randomised controlled trial of plasma exchange and glucocorticoid dosing for severe ANCA-associated vasculitis (AAV). Randomisation is via the internet,

COMPANIES ACT & REGULATIONS - IN OPERATION By Ricardo Wyngaard The Companies Act of 2008 (the Act) and Companies Regulations, 2011 (the ABOUT NPO LEGAL Regulations) came into operation on 01 May 2011. The Act has, to a large extent, been amended by the Companies Amendment Act, 2011. This brief article focuses on some of the key issues that should be taken note of by s21 companies

Copyright © 2010-2014 Medical Articles